ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENGN ENGENE HOLDINGS INC

Market Closed 05-15 16:00:00 EDT

1.72

-0.09

-4.97%

盘后1.66

-0.06-3.45%

19:57 EDT

High1.76	Low1.63	Vol2.75M
Open1.75	D1 Closing1.81	Amplitude7.46%
Mkt Cap115.21M	Tradable Cap64.21M	Total Shares66.98M
T/O4.66M	T/O Rate7.37%	Tradable Shares37.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":1.72,"timestamp":1778875200000,"preClose":1.81,"halted":0,"volume":2750157,"hourTrading":{"tag":"盘后","latestPrice":1.6606,"preClose":1.72,"latestTime":"19:57 EDT","volume":13054,"amount":21967.7687,"timestamp":1778889468808,"change":-0.0594,"changeRate":-0.034535,"amplitude":0.052326},"delay":0,"changeRate":-0.04972375690607739,"floatShares":37332800,"shares":66984661,"eps":-2.2529,"marketStatus":"Market Closed","change":-0.09,"latestTime":"05-15 16:00:00 EDT","open":1.75,"high":1.76,"low":1.625,"amount":4659587.1548802,"amplitude":0.074586,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.2529,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779091200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.81,"preHourTrading":{"tag":"盘前","latestPrice":1.74,"preClose":1.81,"latestTime":"09:29 EDT","volume":34479,"amount":60126.6937518,"timestamp":1778851767035,"change":-0.07,"changeRate":-0.038674,"amplitude":0.044199},"postHourTrading":{"tag":"盘后","latestPrice":1.6606,"preClose":1.72,"latestTime":"19:57 EDT","volume":13054,"amount":21967.7687,"timestamp":1778889468808,"change":-0.0594,"changeRate":-0.034535,"amplitude":0.052326},"volumeRatio":0.37326769554966227,"impliedVol":2.2687,"impliedVolPercentile":0.6667},"requestUrl":"/m/hq/s/ENGN/wiki","defaultTab":"wiki","newsList":[{"id":"2635721973","title":"enGene Holdings Is Maintained at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721973","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721973?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:41","pubTimestamp":1778794860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 17:41 ET (21:41 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635749789","title":"enGene price target lowered to $2 from $9 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2635749789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635749789?lang=en_us&edition=fundamental","pubTime":"2026-05-14 23:24","pubTimestamp":1778772243,"startTime":"0","endTime":"0","summary":"UBS lowered the firm’s price target on enGene (ENGN) to $2 from $9 and keeps a Neutral rating on the shares. Published first on TheFly – the ultima...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-price-target-lowered-to-2-from-9-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-price-target-lowered-to-2-from-9-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","LU3187612489.SGD","BK4585","UBS","BK4588","ENGN","LU1829250122.USD","BK4139","IE0034235071.USD","LU1863844665.USD","BK4118","LU1863844749.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635710134","title":"UBS Adjusts enGene Price Target to $2 From $9, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635710134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635710134?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:53","pubTimestamp":1778763239,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) has an average rating of overweight and mean price target of $8.86, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634184124","title":"enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data Update - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2634184124","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634184124?lang=en_us&edition=fundamental","pubTime":"2026-05-09 18:30","pubTimestamp":1778322642,"startTime":"0","endTime":"0","summary":"Earlier this week, enGene Therapeutics reported interim Phase 2 LEGEND trial results for its bladder cancer gene therapy detalimogene voraplasmid, revealing a 54% complete response rate but weaker 12‑month durability than previously expected, alongside generally manageable side effects and low disease progression.\nThe mixed efficacy profile has triggered analyst downgrades and shareholder-rights investigations, highlighting how a single data update can rapidly reshape perceptions of a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-therapeutics/news/engene-therapeutics-engn-is-down-806-after-mixed-phase-2-bla","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-engn/engene-therapeutics/news/engene-therapeutics-engn-is-down-806-after-mixed-phase-2-bla","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LENZ","ENGN","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634464947","title":"enGene Therapeutics announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2634464947","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634464947?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:08","pubTimestamp":1778270927,"startTime":"0","endTime":"0","summary":"Shareholders to vote on election of four directors for terms running to 2029, including Philip Astley-Sparke, Ronald H.W. Cooper, William Grossman, Michael Heffernan.Ballot also includes appointment of KPMG as auditor for ensuing year, including authorization for board to set auditor remuneration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL9hRNRj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633456856","title":"Citizens Downgrades enGene to Market Perform From Market Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2633456856","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633456856?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:13","pubTimestamp":1778242422,"startTime":"0","endTime":"0","summary":"enGene (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633095455","title":"Piper Sandler Downgrades enGene Holdings to Neutral From Overweight, Adjusts Price Target to $4 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2633095455","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633095455?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:10","pubTimestamp":1778242247,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) has an average rating of overweight and mean price target of $11.05, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633045332","title":"enGene Holdings Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633045332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633045332?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:29","pubTimestamp":1778239740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 07:29 ET (11:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633430197","title":"enGene Holdings (ENGN) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2633430197","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633430197?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:58","pubTimestamp":1778237881,"startTime":"0","endTime":"0","summary":"In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on enGene Holdings, with a price target of $6.00. Acco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/engene-holdings-engn-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/engene-holdings-engn-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633319437","title":"enGene Therapeutics Inc. : Wells Fargo Cuts Target Price to $2 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2633319437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633319437?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:33","pubTimestamp":1778236429,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nAZN4SV5MM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633434706","title":"enGene Holdings Cut to Neutral From Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2633434706","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633434706?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:10","pubTimestamp":1778235000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 06:10 ET (10:10 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633143618","title":"enGene downgraded to Market Perform from Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2633143618","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633143618?lang=en_us&edition=fundamental","pubTime":"2026-05-08 17:00","pubTimestamp":1778230814,"startTime":"0","endTime":"0","summary":"Citizens downgraded enGene (ENGN) to Market Perform from Outperform without a price target The company’s updated results from the pivotal LEGEND st...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-downgraded-to-market-perform-from-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-downgraded-to-market-perform-from-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633480417","title":"enGene Therapeutics Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $4 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2633480417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633480417?lang=en_us&edition=fundamental","pubTime":"2026-05-08 15:32","pubTimestamp":1778225533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41K1O8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633087108","title":"enGene downgraded to Neutral from Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2633087108","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633087108?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:51","pubTimestamp":1778190704,"startTime":"0","endTime":"0","summary":"Guggenheim downgraded enGene (ENGN) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633259501","title":"enGene announces updated interim results from LEGEND cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2633259501","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633259501?lang=en_us&edition=fundamental","pubTime":"2026-05-07 22:15","pubTimestamp":1778163338,"startTime":"0","endTime":"0","summary":"enGene (ENGN) Therapeutics reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene vorapla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/engene-announces-updated-interim-results-from-legend-cohort-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/engene-announces-updated-interim-results-from-legend-cohort-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633407241","title":"EnGene Therapeutics Shares Sink After Cancer Study Durability Outcomes Disappoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2633407241","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633407241?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:15","pubTimestamp":1778159700,"startTime":"0","endTime":"0","summary":"Shares of EnGene Therapeutics plummeted after the company reported disappointing durability outcomes from a Phase 2 trial of its detalimogene voraplasmid drug for bladder cancer patients.The stock fell 73% to $2.36 in premarket trading. Through Wednesday's close, shares had more than doubled over the past 12 months.The company said the estimate for median duration of response was 37.3 weeks. The estimate of the 12-month duration of response was 25%.\"While durability outcomes to date are not what we hoped, these data are preliminary,\" said Chief Executive Ron Cooper.EnGene also said that among the 32 patients who had their first disease assessment after the last data analysis, complete response rates were lower than previously reported results.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ENGN","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145195","title":"enGene reports 43% six-month complete response in Phase 2 LEGEND bladder cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145195","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145195?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:08","pubTimestamp":1778152128,"startTime":"0","endTime":"0","summary":"enGene Therapeutics reported updated interim results from Phase 2 LEGEND pivotal cohort testing detalimogene in high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with data cut as of April 21, 2026.Responses were seen in more than half of treated patients at some point, with fewer patients remaining cancer-free at later follow-ups, raising durability questions.Disease worsening to more advanced stages remained uncommon, supporting continued use of bladder-sparing approaches for many patients.Safety profile stayed broadly manageable, with most treatment-related side effects mild and few patients stopping therapy due to adverse events.Results will be presented at plenary session during American Urological Association meeting on May 15, 2026, with FDA discussions continuing ahead of potential BLA filing and update expected in second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL8Pkfw4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633514505","title":"enGene Therapeutics Inc - Detaimigene Achieves 54% Complete Response at Any Time, 43% at Six Months as of April 21, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633514505","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633514505?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA8YP0MF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145045","title":"enGene Therapeutics Inc - 2.4% Experienced Treatment Interruption, 2.4% Discontinuation Due to Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145045?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA8YP0MF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145032","title":"enGene Therapeutics Inc - 55% Experienced Treatment-Related Adverse Events of Detalimogene, Mostly Mild","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145032","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145032?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nTUA8YP0MF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.engene.com","stockEarnings":[{"period":"1week","weight":0.1467},{"period":"1month","weight":-0.7784},{"period":"3month","weight":-0.8241},{"period":"6month","weight":-0.7984},{"period":"1year","weight":-0.4941},{"period":"ytd","weight":-0.8095}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.","exchange":"NASDAQ","name":"ENGENE HOLDINGS INC","nameEN":"ENGENE HOLDINGS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENGENE HOLDINGS INC,ENGN,ENGENE HOLDINGS INC股票,ENGENE HOLDINGS INC股票老虎,ENGENE HOLDINGS INC股票老虎国际,ENGENE HOLDINGS INC行情,ENGENE HOLDINGS INC股票行情,ENGENE HOLDINGS INC股价,ENGENE HOLDINGS INC股市,ENGENE HOLDINGS INC股票价格,ENGENE HOLDINGS INC股票交易,ENGENE HOLDINGS INC股票购买,ENGENE HOLDINGS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}